title: High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy.
abstract: OBJECTIVE
  We have developed a new rat model that mimics the natural course of diabetic nephropathy seen in type 2 diabetes.
  
  
  METHODS
  Nine days after intravenous injection of streptozotocin (STZ) (40 mg/kg) or vehicle to 8-week-old male Sprague-Dawley rats, the animals' right kidneys were surgically removed. Two weeks after surgery, the STZ-injected rats were fed on either a high-fat (ST+HF) or a normal (ST) diet, while the vehicle-injected rats were fed on the high-fat diet (HF).
  
  
  RESULTS
  Baseline biochemical markers did not differ between the three groups. Only the ST+HF group showed a significant increase in plasma glucose levels after 15 weeks, and simultaneously plasma insulin levels started to decrease, followed by an increase in plasma total cholesterol and triglyceride levels at 25 weeks and slightly later by an increase in blood pressure. In the ST+HF group, significant microalbuminuria was detected at 15 weeks followed by overt proteinuria, both of which were absent in the other two groups. Also in ST+HF, the creatinine clearance rate increased until week 15, and then gradually decreased. Histologically, ST+HF rats showed mesangial expansion at week 25, and diffuse glomerular sclerosis at the end of the experiments.
  
  
  CONCLUSIONS
  The chronological changes in biochemical, physiological and histological markers in ST+HF rats are reminiscent of human type 2 diabetes and nephropathy. Our new model of type 2 diabetic nephropathy should help us to understand the pathophysiology of the disease and serve to explore measures to prevent and treat diabetic nephropathy.
authors.affiliation: Kureha Corp., Tokyo 169-8503, Japan.
authors.forename: Mikio
authors.initials: M
authors.lastname: Sugano
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Yamato
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Hayashi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Ochiai
authors.forename: Junji
authors.initials: J
authors.lastname: Kakuchi
authors.forename: Sumie
authors.initials: S
authors.lastname: Goto
authors.forename: Fuyuhiko
authors.initials: F
authors.lastname: Nishijima
authors.forename: Noriaki
authors.initials: N
authors.lastname: Iino
authors.forename: Junichiro James
authors.initials: JJ
authors.lastname: Kazama
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Osamu
authors.initials: O
authors.lastname: Mokuda
authors.forename: Toshio
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Ryo
authors.initials: R
authors.lastname: Okazaki
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies; D004041:Dietary Fats / Q000008:administration & dosage; D008297:Male; D009392:Nephrectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin
chemical_list: D004041:Dietary Fats; D013311:Streptozocin